NEW ONLINE FEATURE!
A Message from Bradley Bale, MD and Amy Doneen, DNP, ARNP
Genetics will drive the future of healthcare and enhance precision medicine, which is now endorsed by the National Institutes of Health and the U.S. National Research Council. We are proud to introduce our new, accredited CME genetic webcast series for clinicians explaining the clinical utility of newly available genetic tests to identify cardiovascular (CV) risk and how data from these tests can improve patient management. Simple therapies to potentially enhance the CV health of at-risk patients will also be discussed.
Advance your scientific knowledge by taking our four courses together or individually and receive cost-effective CME credits. View our CME webcasts conveniently at home or in your office, then take an online exam. To download our Online Genetics CME Course brochure, click here, A score of 70% or higher is required to get a certificate of completion for these courses:
- Bale Doneen Method Genetic Online Course: Clinical Application of Genetic Testing to Enhance Cardiovascular Care: Atrial Fibrillation-AF and 4Q25. Approved for up to 1.5 prescribed credits by the American Academy of Family Physicians (AAFP). Speaker: Amy L. Doneen, DNP, ARNP.
This program demonstrates the clinical application of genetic testing through the lens of atrial fibrillation (AF) and the 4Q25 gene. This CME brings the latest data on AF, which affects 33 million Americans, and genetic testing for the 4Q25 gene that raises AF risk by up to 70% into the arena of family practice, specifically focusing on early diagnostics, prevention and monitoring of this common and dangerous cardiac arrhythmia through individualized patient management.
- Bale Doneen Method Genetic Online Course: Clinical Application of Genetic Testing to Enhance Cardiovascular Care: Familial Hypercholesterolemia-FH. Approved for up to 1 prescribed credit by the AAFP. Speaker: Bradley F. Bale, MD.
Patients with familial hypercholesterolemia (FH) have a five times higher risk of cardiovascular (CV) mortality if untreated. Studies report that only 20% of those with FH are currently diagnosed. This CME covers genetic testing to identify patients with homozygous FH (HoFH), a rare genetic disease that creates significant risk for a fatal heart attack before age 20; and heterozygous FH, a relatively common disease that raises risk for CV events in young adults. New therapies are available to significantly reduce CV risk in HoFH and HeFH patients.
- Bale Doneen Method Genetic Online Course: Clinical Application of Genetic Testing to Enhance Cardiovascular Care: Haptoglobin-Hp. Approved for up to 1.5 prescribed credits by the AAFP. Speaker: Bradley F. Bale, MD.
Haptoglobin genotype is a screening for type 2 diabetic patients at risk for cardiovascular disease (CVD. This CME elucidates the key functional differences in the Hp 1 genotype versus Hp 2, as well as the potential role of Hp 2’s precursor protein, zonulin, in autoimmune disease and cancer risk. Simple therapies to potentially enhance the health of Hp 2 patients will be discussed and how to personalize care through Hp genotyping.
- Bale Doneen Method Genetic Online Course: Women and CVD. Approved for up to 1 prescribed credit by the AAFP. Speaker: Amy L. Doneen, DNP, ARNP.
Currently 65% of women who die suddenly of a heart attack didn’t know they had have heart disease. Women at high risk of CVD are often missed using standard-of-care evaluation techniques. This CME focuses on the uniqueness of women with special attention to their cardiovascular red flags, genetic testing and specific treatment recommendations critical to allow women optimal cardiovascular wellness.
Bale Doneen Method Online Genetic CME Course
Where: Digital Chalk
(Sign up for an account, then register for the CME courses)
When: Available anytime at https://ioa.digitalchalk.com
Your Price: $125 per course, or $400 to take all four courses ($100 savings).
Click here to read the Genetic CME Series brochure.
Sign-Up for the Course